Cislini Jeff 4

What Happened
Jeff Cislini, General Counsel of Revolution Medicines (RVMD), reported the sale of 2,157 shares on June 16, 2026. The shares were sold in open-market transactions at a weighted average price of $156.12 per share for total proceeds of approximately $336,749. The sale was executed in multiple trades with prices ranging from $156.1105 to $156.8251.

Key Details

• Transaction date: June 16, 2026; Form 4 filed June 18, 2026 (appears timely).
• Transaction type: Sale (S) — 2,157 shares; weighted average price $156.12; proceeds ~$336,749.
• Price range: $156.1105 to $156.8251; weighted average reported. Reporting person can provide trade-level details on request.
• Footnote F1: Sale made pursuant to a Rule 10b5-1 plan adopted May 31, 2023 to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023.
• Footnote F3/F4: Filing notes include 43,514 RSUs and 160 shares acquired under the ESPP on May 31, 2026. The filing excerpt provided does not state a single consolidated "shares owned after transaction" total.

Context
This sale was executed under a pre-established 10b5-1 plan to cover tax withholding tied to RSU vesting, which is a common, non-discretionary reason for insider sales and not necessarily an indicator of company outlook. The filing discloses the sale details and the nature of the plan; no additional inference about insider sentiment should be made from this routine, tax-related transaction.